Calcium Pantothenate

In the fields of vitamin supplements, functional feed additives and nutritional preparations, calcium pantothenate is one of the core substances of B vitamins. As a precursor of coenzyme A, it participates in the metabolic processes of the three major nutrients in the body: carbohydrates, proteins and fats, and maintains the normal function of epithelial cells and the integrity of mucosal barrier. On the clinical level, calcium pantothenate can be used for the prevention and treatment of pantothenic acid deficiency and the adjuvant treatment of vitamin B complex deficiency. It is also suitable for absorption disorders and postoperative nutritional supplementation, and the applicable population covers people with insufficient daily dietary intake and people who need additional supplementation in special physiological stages. In the field of animal husbandry and breeding, calcium pantothenate is an essential component of feed additives, which can improve the growth performance and immunity of livestock and poultry, and is a rigidly demanded raw material for the feed industry.

At present, the global market size of calcium pantothenate is approximately USD 1.2 billion, with a compound annual growth rate maintained at around 4.5%. The market concentration is relatively high, and most of the leading enterprises are concentrated in China. Domestic production capacity accounts for more than 80% of the total global production capacity, and industry competition presents three core dimensions: leading production capacity, cost advantage and compliance qualification. In recent years, with the upgrading of nutritional and health demands and the improvement of feed additive standards, the market demand for calcium pantothenate has maintained a steady growth, and its price shows periodic adjustments affected by the price fluctuation of upstream raw materials and environmental protection policies.

The original research enterprise of calcium pantothenate is Daiichi Pharmaceutical Co., Ltd. of Japan, and the original research product is calcium pantothenate tablets. Its core compound patents have expired worldwide. The main dosage forms of the original research product include oral tablets, with conventional specifications of 5mg and 10mg. Among them, the 10mg specification of calcium pantothenate tablets has been included in the Chinese *Catalogue of Chemical Drugs* and also listed in the FDA Reference Listed Drug Directory. At present, the calcium pantothenate API of a number of domestic enterprises have completed the registration with CDE, with the associated review status of A. Multiple specifications of calcium pantothenate tablets and multivitamin preparations have been approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for calcium pantothenate API, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can meet the qualitative and quantitative detection requirements for impurities in the whole process of API R&D, quality research and registration declaration, providing stable support for enterprises to shorten the R&D cycle and reduce compliance risks.